mivenion GmbH, the leading company in optical imaging of arthritis, will exhibit its groundbreaking Rheumascan workstation  Xiralite® X4  and the most advanced XiraView 3.6 software for diagnostic imaging of inflammation in the hands at the forthcoming annual European Congress of Radiology (ECR) in Vienna, Austria, March 4-7. The ECR is one of the largest medical meetings worldwide and the second largest radiological congress, with around 19,000 participants from all over the world. Parallel to the Xiralite workstation, mivenion will feature key results of clinical studies using the system in comparison with clinical exam, power Doppler ultrasound, and contrast-enhanced MRI.

Xiralite® X4 induces the fluorescence of ICG using light-emitting diodes (LED) and quantitatively records the fluorescence emitted in all joints of both hands. Thus active inflammation can be simultaneously diagnosed in up to 30 joints. Signal differences usually result from different "wash-in"/ "wash out" kinetics of the contrast agent at the site of inflammation. The fluorescence camera system Xiralite® X4 is optimized to detect even very low amounts of the contrast agent ICG and thereby enables the diagnosis of small inflammatory lesions. Signal intensity, localization of the signal, and the time period of enhancement are relevant for differential diagnosis. The procedure is suited for detection of early onset of inflammation in joints, as well as for monitoring of antiinflammatory therapies. The differential diagnosis of different diseases is a further application of Rheumascan.

“Rheumascan using the most advanced software version XiraView 3.6 reliably detects clinically active inflammation in the hands. Very surprisingly, we demonstrated a high specificity in healthy volunteers where almost no pathologic signal intensities are present. I personally believe that Rheumascan will be the future standard to exclude active disease in patients with unclear joint pain, to identify early arthritis, to discriminate between inflammatory and non-inflammatory pain disorders, and potentially to follow disease activity and evaluate anti-inflammatory therapeutic outcome” as stated by Dr. Malte Bahner, radiologist and responsible for clinical development at mivenion GmbH.